The US patent is titled ‘Intermediate Compounds and Processes for the Preparation of Tapentadol and Related Compounds’.
Using easily available reagents, the patented and cost effective process fitting scalable industrial process aids in producing optically active pure form of Tapentadol.
Mapi Pharma president and CEO Ehud Marom said in addition to the present patent, the company obtained first patent for a long acting depot formulation of Glatiramer Acetate for the treatment of MS.
"Both patents strengthen Mapi’s patent position, support the business plan and advance the company one step closer to bringing patients improved medications at affordable prices," Marom added.
"The pain relief market requires a specific expertise in dealing with potent pharmaceuticals. Mapi is uniquely positioned to answer the growing needs of this market."